Clin2
NCT07741006Possibly a fitEnrolling by invitation

PET imaging study for adults with solid tumors

Malignant Solid Tumor

Part of Cancer clinical trials.

This study tests a new PET imaging agent called [68Ga]Ga-ELI411 to help see tumors more clearly. It is for adults with solid tumors who are already scheduled for a standard PET scan, and may help doctors better understand and manage their cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
18 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 years or older.
  • You have a confirmed solid tumor (diagnosed by biopsy, cytology, or clinical findings).
  • You are already scheduled for a standard FDG PET scan.
  • You are in good general health (able to perform daily activities, with no major health problems).
  • If you can become pregnant, you must have a negative pregnancy test before the scan and agree to use effective birth control during the study and for 6 months after.
  • You are not pregnant, breastfeeding, or allergic to gallium-based imaging agents or ethanol.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT05629689Recruiting· Phase 1
PET scan drug check for people with solid tumors

This Phase 1 study tests whether an investigational PET scan tracer is safe and tolerable when used for PET imaging in people with certain solid cancers. It mainly looks at side effects and how well the scan can be done, not whether it treats cancer.

Amsterdam
NCT07708103Not yet recruiting· Early Phase 1
Testing a new PET scan agent for solid tumors

This study tests a new PET/CT imaging agent (gallium-68 FFD) to see how well it works in both healthy volunteers and people with solid tumors. It could help doctors find or monitor cancer more accurately.

Wuhan, Hubei
NCT07420036Not yet recruiting· Early Phase 1
Testing a new PET scan tracer for detecting cancer

This trial tests a new radioactive tracer called 68Ga-SFB6-ZN01 for PET/CT scans in people with suspected or confirmed solid tumors. It aims to see if this tracer can help find cancer or detect recurrence after treatment.

Wuhan, Hubei
NCT07689656Recruiting· Phase 1/Phase 2
PET imaging study for prostate cancer using a new tracer

This trial tests a new radioactive tracer called ELI421 to see how well it works for PET imaging in people with prostate cancer. It may help doctors find cancer more clearly.

Wuhan, Hubei
NCT07385950Not yet recruiting
Evaluating a new PET imaging agent for solid tumors

This study tests a new imaging agent that lights up certain proteins on solid tumors during a PET scan. It may help doctors better see tumors and guide treatment decisions.

Wuhan, Hubei
NCT06719856Recruiting
PET imaging study for multiple solid tumors

This trial uses a special PET scan to take pictures of certain solid tumors. The scan uses a new dye that may help doctors see the tumors more clearly. You may be eligible if you have one of the listed cancers and are between 18 and 75 years old with good daily function.

Beijing, Beijing Municipality

Hear when a new Malignant Solid Tumor trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.